Editorial Commentary
Antithrombotic therapy after coronary artery stenting in atrial fibrillation: dual therapy encompassing NOAC plus P2Y12 inhibitor is ready for prime time!
Abstract
Non-vitamin k antagonist oral anticoagulants (NOACs) are drugs of choice for the majority of patients with atrial fibrillation (AF) to prevent cerebral strokes (1). The risk for stroke in AF patients is determined by concomitant clinical factors, which are summarized in the CHA2DS2-Vasc risk score (2).
